Skip to main content
Quest Diagnostics

Frequency and Implications of Likely Maternal Segmental Aneusomies on Cell-free DNA Prenatal Screening

ACMG Annual Clinical Genetics meeting 2025

American College of Medical Genetics

Los Angeles, CA, Mar 18-21 , 2025

Oral presentation: Frequency and Implications of Likely Maternal Segmental Aneusomies on Cell-free DNA Prenatal Screening

Authors: South S, Ahram D, Anderson B, Blazejewski L, Cai G, Ghaffari G, Liao M, Livingston K, Niemchak T, Oddoux C, Quan F, Rion J, Sharma M, Vo T, Wang G, Xie Y, Yang H

Specialty: Genetics, Women's Health, OB, GYN

Related content

Test FAQ
QNatal Advanced
Publication
Multisite Evaluation and Validation of Optical Genome Mapping for Prenatal Genetic Testing
Conference Presentation
The Proportion of Reportable cfDNA Screening Results for Fetal Aneuploidy in Pregnancies Less Than 10 Weeks Gestation
Test FAQ
Chromosome Analysis, POC Tissue
Test FAQ
Maternal Serum AFP

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.